Key Points:

• Orion180 Insurance is targeting a $340 million IPO at $15 to $17 per share, giving investors exposure to the expanding excess and surplus homeowners insurance market.
• Electra Therapeutics is pursuing a $346.7 million offering at $14 to $16 per share, making biotech one of the most significant sources of new U.S. equity issuance in the current session.
• The broader calendar shows 11 IPO-related pricing events, but the concentration of conventional operating-company listings in insurance and biotechnology makes these two transactions the clearest tests of institutional demand.

Insurance and Biotech Put the IPO Window to the Test

The U.S. IPO market enters September 17 with two notable operating-company offerings at the center of investor attention: Orion180 Insurance and Electra Therapeutics. Orion180 is targeting approximately $340 million at a proposed $15 to $17 per share, while Electra Therapeutics is targeting about $346.7 million at $14 to $16. Together, the offerings represent nearly $687 million of potential gross proceeds and provide a useful read on demand across two very different sectors. Their pricing will help establish how much capital investors are prepared to commit to financial and biotechnology businesses as the fall issuance window develops.

Orion180 Brings Insurance Growth to the Public Market

Orion180 is positioning its IPO around the U.S. excess and surplus, or E&S, homeowners insurance market, an area that has expanded as traditional insurers have reduced exposure to catastrophe-prone properties. The company operates across 14 states and had approximately $601 million in managed premiums written during the 12 months ended June 30, 2026, according to its IPO materials. More than 670,000 policies have been sold since inception.

The proposed $15 to $17 range implies gross proceeds of approximately $300 million to $340 million before any over-allotment. Orion180 plans to list on Nasdaq under the ticker OIG. For investors, the transaction offers a direct test of whether public markets will place a premium on specialized insurance platforms that combine underwriting, technology and distribution rather than relying on the traditional carrier model.

Electra Extends the Biotech IPO Recovery

Electra Therapeutics brings a different form of growth exposure to the market. The South San Francisco biotechnology company is developing antibody-based therapies targeting signal regulatory proteins for immune diseases and cancer. Its lead candidate, ipsoprubart, is being evaluated in a registrational Phase 2/3 program for secondary hemophagocytic lymphohistiocytosis, while its broader pipeline provides additional potential applications in immune-mediated disease and oncology.

Electra plans to offer approximately 21.67 million shares at $14 to $16, translating into potential gross proceeds of roughly $303 million to $347 million depending on the final price. The company expects to list on Nasdaq under ETRA. The transaction is particularly relevant to the IPO market because biotechnology issuance remains highly sensitive to investor appetite for companies whose valuations depend heavily on clinical progress and future product commercialization.

The Calendar Shows Broader Activity, but Quality Matters

The supplied IPO calendar records 11 pricing events for September 17, including Orion180 and Electra as well as SPAC-related securities and newly listed ETF products. That headline count indicates a busy primary-market schedule, but the composition is more important than the raw number of events. SPAC units, warrants and ETFs have different capital-market dynamics from conventional operating-company IPOs.

For institutional investors, Orion180 and Electra therefore provide the stronger signals on the health of the traditional IPO window. Their pricing levels, allocation quality and subsequent trading behavior can influence how other issuers approach valuations and deal sizes later in September.

Pricing Will Set the Next Market Signal

The immediate focus is on where Orion180 and Electra ultimately price relative to their proposed ranges and how the shares perform once public trading begins. Strong execution would reinforce the ability of differentiated companies to access public equity capital, while weaker pricing could encourage issuers to moderate valuations or adjust offering structures. With additional transactions already moving through the September pipeline, the market is entering a period in which individual IPO outcomes will increasingly shape expectations for the broader U.S. issuance window.